Ovid Therapeutics Inc OVID

Morningstar Rating
$2.35 −0.07 (2.70%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

OVID is trading at a LOCK|^CY&$h premium.
Price
$2.41
Fair Value
LOCK|<gng<#
Uncertainty
LOCK|Y? @yR^
1-Star Price
LOCK|QsY&^d
5-Star Price
LOCK|NRX#>>
Economic Moat
LOCK|^@
Capital Allocation

Trading Information

Previous Close Price
$2.41
Day Range
$2.342.39
52-Week Range
$0.483.10
Bid/Ask
$2.34 / $2.35
Shares Outstanding
186.64M
Market Cap
$438.60M
Volume/Avg
304,450 / 2M

Key Statistics

Price/Earnings (Normalized)
Price/Sales
30.84
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
23

Valuation

Metric
OVID
Price/Earnings (Normalized)
Price/Book Value
2.03
Price/Sales
30.46
Price/Cash Flow
Price/Earnings
OVID

Financial Strength

Metric
OVID
Quick Ratio
9.88
Current Ratio
10.17
Interest Coverage
Quick Ratio
OVID

Profitability

Metric
OVID
Return on Assets (Normalized)
−33.96%
Return on Equity (Normalized)
−41.66%
Return on Invested Capital (Normalized)
−36.52%
Return on Assets
OVID

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|>d$!#LQLOCK|zH>@$123B
Regeneron Pharmaceuticals Inc
REGN
LOCK|%$c#g$?LOCK|>f>D$71B
argenx SE ADR
ARGX
LOCK|^LF#%rMLOCK|#^b$54B
BeOne Medicines Ltd ADR
ONC
LOCK|#G>fvgWLOCK|rj$36B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|&Q$&%#BLOCK|%pj%?$36B
Royalty Pharma PLC Class A
RPRX
LOCK|&$z>DNQ>LOCK|rfX!$26B
Moderna Inc
MRNA
LOCK|gG>HCxLOCK|b<$25B
Incyte Corp
INCY
LOCK|^@C!W>LOCK|xB$23B
BioNTech SE ADR
BNTX
LOCK|ZFQd?<fLOCK|&Q$23B
BridgeBio Pharma Inc
BBIO
LOCK|%Z!%gk^LOCK|#l$16B

Sponsor Center